Upfront combination lipid-lowering therapy in acute coronary syndrome: a bayesian network meta-analysis of low-density lipoprotein cholesterol reduction and major adverse cardiovascular events
Acute coronary syndrome (ACS) is a leading cause of death worldwide. Guidelines recommend initiation of high-intensity statin therapy after ACS, followed by combination therapy in patients who are unable to achieve target low-density lipoprotein cholesterol (LDL-C) lowering. Upfront combination lipid-lowering the...